Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation [3]

Blood

Volumn 110, Issue 8, 2007, Pages 3083-

  Platzbecker, Uwe ^a   Ehninger, Gerhard ^b   Bornhäuser, Martin ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON CHELATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; DECISION MAKING; FERRITIN BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; IRON OVERLOAD; LETTER; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 35548951876     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-089839     Document Type: Letter

References (3)

1. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586-4588.
2. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.
3. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.